These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15824194)

  • 1. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction.
    Ackerman Z; Oron-Herman M; Grozovski M; Rosenthal T; Pappo O; Link G; Sela BA
    Hypertension; 2005 May; 45(5):1012-8. PubMed ID: 15824194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease.
    Ackerman Z; Skarzinski G; Grozovski M; Oron-Herman M; Sela BA
    Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):545-51. PubMed ID: 24975050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
    Ackerman Z; Grozovski M; Oron-Herman M; Rosenthal T; Sela BA; Amir G
    Basic Clin Pharmacol Toxicol; 2013 Jul; 113(1):37-42. PubMed ID: 23489555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.
    Ackerman Z; Oron-Herman M; Rosenthal T; Pappo O; Link G; Sela BA; Grozovski M
    Dig Dis Sci; 2008 Mar; 53(3):777-84. PubMed ID: 17710547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk reduction therapy for syndrome X: comparison of several treatments.
    Oron-Herman M; Sela BA; Rosenthal T
    Am J Hypertens; 2005 Mar; 18(3):372-8. PubMed ID: 15797656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
    Ackerman Z; Oron-Herman M; Pappo O; Peleg E; Safadi R; Schmilovitz-Weiss H; Grozovski M
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):663-8. PubMed ID: 20210788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fructose supplementation worsens the deleterious effects of short-term high-fat feeding on hepatic steatosis and lipid metabolism in adult rats.
    Crescenzo R; Bianco F; Coppola P; Mazzoli A; Tussellino M; Carotenuto R; Liverini G; Iossa S
    Exp Physiol; 2014 Sep; 99(9):1203-13. PubMed ID: 24972835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.
    Fujioka Y; Masai M; Tsuboi S; Okumura T; Morimoto S; Tsujino T; Ohyanagi M; Iwasaki T
    Hypertens Res; 2003 Jan; 26(1):111-6. PubMed ID: 12661920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats.
    Si X; Webb RC; Richey JM
    Can J Physiol Pharmacol; 1999 Oct; 77(10):755-62. PubMed ID: 10588479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatoprotective potential of zingerone against nonalcoholic fatty liver disease in rats fed with fructose-enriched diet.
    Muniandy Narayanan J; Jesudoss VA
    Gen Physiol Biophys; 2016 Apr; 35(2):185-94. PubMed ID: 26915720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats.
    de Castro UG; dos Santos RA; Silva ME; de Lima WG; Campagnole-Santos MJ; Alzamora AC
    Lipids Health Dis; 2013 Sep; 12():136. PubMed ID: 24044579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides.
    Matsui H; Okumura K; Kawakami K; Hibino M; Toki Y; Ito T
    Diabetes; 1997 Mar; 46(3):348-53. PubMed ID: 9032088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats.
    Bagul PK; Middela H; Matapally S; Padiya R; Bastia T; Madhusudana K; Reddy BR; Chakravarty S; Banerjee SK
    Pharmacol Res; 2012 Sep; 66(3):260-8. PubMed ID: 22627169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Sitosterol mitigates the development of high-fructose diet-induced nonalcoholic fatty liver disease in growing male Sprague-Dawley rats.
    Gumede NM; Lembede BW; Nkomozepi P; Brooksbank RL; Erlwanger KH; Chivandi E
    Can J Physiol Pharmacol; 2020 Jan; 98(1):44-50. PubMed ID: 31560861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Amyrin attenuates high fructose diet-induced metabolic syndrome in rats.
    Prabhakar P; Reeta KH; Maulik SK; Dinda AK; Gupta YK
    Appl Physiol Nutr Metab; 2017 Jan; 42(1):23-32. PubMed ID: 27911087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of supplementation with biotin against high-fructose-induced metabolic syndrome in rats.
    Aguilera-Mendez A; Hernández-Equihua MG; Rueda-Rocha AC; Guajardo-López C; Nieto-Aguilar R; Serrato-Ochoa D; Ruíz Herrera LF; Guzmán-Nateras JA
    Nutr Res; 2018 Sep; 57():86-96. PubMed ID: 30122199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
    Schmilovitz-Weiss H; Hochhauser E; Cohen M; Chepurko Y; Yitzhaki S; Grossman E; Leibowitz A; Ackerman Z; Ben-Ari Z
    Lipids Health Dis; 2013 Mar; 12():41. PubMed ID: 23531105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.